Abstract:In addition to cis-cleavage activity that recognizes and cleaves nucleic acid sequences, a trans-cleavage activity that indiscriminately and non-specifically cleaves single-stranded DNA or RNA has been discovered in some Cas proteins, including Cas12a and Cas13a. Various detection methods using this activity have been widely reported. Herein, we describe a new highly efficient DNA reporter (5′-TTATT-CCCCC-3′; TTATT-5C) that outperformed the existing AT-rich DNA reporter (5′-TTATT-3′) used in most Cas12a-based … Show more
“…We also note that ssDNA activation shows stronger trans-cleavage activity than that of dsDNA for both the WT and Mut, which complements the results summarized in Figure and is consistent with the observations of Huyke et al . Note that the Cas12a kinetic parameters measured in this work ( k cat around 0.4 s –1 and K M around 0.3 μM) are comparable to parameters reported by Huyke et al, Rossetti et al, and Lee et al See Table S11 for the kinetic parameters measured in this work.…”
Section: Resultssupporting
confidence: 92%
“…We next evaluated reported sequences for ssDNA fluorescent reporters and analyzed three of these in more detail. Lee et al compared 11 reporter sequences to maximize Cas12a trans-cleavage activity. They identified the most efficient sequence (5′-TTATT-CCCCC-3′, hereafter termed 5C) and claimed a 10-fold increase in sensitivity compared to the most commonly used reporter sequence (5′-TTATT-3′, hereafter TTATT).…”
Next-generation sequencing offers highly multiplexed and accurate detection of nucleic acid sequences but at the expense of complex workflows and high input requirements. The ease of use of CRISPR-Cas12 assays is attractive and may enable highly accurate detection of sequences implicated in, for example, cancer pathogenic variants. CRISPR assays often employ endpoint measurements of Cas12 trans-cleavage activity after Cas12 activation by the target; however, end point-based methods can be limited in accuracy and robustness by arbitrary experimental choices. To overcome such limitations, we develop and demonstrate here an accurate assay targeting a mutation of the epidermal growth factor gene implicated in lung cancer (exon 19 deletion). The assay is based on characterizing the kinetics of Cas12 trans-cleavage to discriminate the mutant from wild-type targets. We performed extensive experiments (780 reactions) to calibrate key assay design parameters, including the guide RNA sequence, reporter sequence, reporter concentration, enzyme concentration, and DNA target type. Interestingly, we observed a competitive reaction between the target and reporter molecules that has important consequences for the design of CRISPR assays, which use preamplification to improve sensitivity. Finally, we demonstrate the assay on 18 tumor-extracted amplicons and 100 training iterations with 99% accuracy and discuss discrimination parameters and models to improve wild type versus mutant classification.
“…We also note that ssDNA activation shows stronger trans-cleavage activity than that of dsDNA for both the WT and Mut, which complements the results summarized in Figure and is consistent with the observations of Huyke et al . Note that the Cas12a kinetic parameters measured in this work ( k cat around 0.4 s –1 and K M around 0.3 μM) are comparable to parameters reported by Huyke et al, Rossetti et al, and Lee et al See Table S11 for the kinetic parameters measured in this work.…”
Section: Resultssupporting
confidence: 92%
“…We next evaluated reported sequences for ssDNA fluorescent reporters and analyzed three of these in more detail. Lee et al compared 11 reporter sequences to maximize Cas12a trans-cleavage activity. They identified the most efficient sequence (5′-TTATT-CCCCC-3′, hereafter termed 5C) and claimed a 10-fold increase in sensitivity compared to the most commonly used reporter sequence (5′-TTATT-3′, hereafter TTATT).…”
Next-generation sequencing offers highly multiplexed and accurate detection of nucleic acid sequences but at the expense of complex workflows and high input requirements. The ease of use of CRISPR-Cas12 assays is attractive and may enable highly accurate detection of sequences implicated in, for example, cancer pathogenic variants. CRISPR assays often employ endpoint measurements of Cas12 trans-cleavage activity after Cas12 activation by the target; however, end point-based methods can be limited in accuracy and robustness by arbitrary experimental choices. To overcome such limitations, we develop and demonstrate here an accurate assay targeting a mutation of the epidermal growth factor gene implicated in lung cancer (exon 19 deletion). The assay is based on characterizing the kinetics of Cas12 trans-cleavage to discriminate the mutant from wild-type targets. We performed extensive experiments (780 reactions) to calibrate key assay design parameters, including the guide RNA sequence, reporter sequence, reporter concentration, enzyme concentration, and DNA target type. Interestingly, we observed a competitive reaction between the target and reporter molecules that has important consequences for the design of CRISPR assays, which use preamplification to improve sensitivity. Finally, we demonstrate the assay on 18 tumor-extracted amplicons and 100 training iterations with 99% accuracy and discuss discrimination parameters and models to improve wild type versus mutant classification.
“…For instance, when employing Cas12a/Cas13a, the presence of cis -cleavage activity can adversely affect amplification efficiency, making it challenging to achieve a one-pot approach, and the cumulative errors introduced through multiple steps are non-negligible. 133,134…”
“…34 In addition, Han et al proposed an isothermal amplification strategy by employing Cas12a-based primer production for sensitive nucleic acid quantification. 35 The trans-cleavage activity of CRISPR-Cas12a enables highly efficient digestion of ssDNA sequences after recognizing target sequences, 36 making it a promising tool to develop a sensitive and reliable colorimetric method. 37,38 Herein, we propose a novel colorimetric approach for sensitive and reliable P. aeruginosa analysis by integrating selfprimer-based production of ssDNA and CRISPR-Cas12aassisted color development.…”
Pseudomonas aeruginosa
(
P. aeruginosa
) is a common opportunistic
Gram-negative
pathogen that may cause infections to immunocompromised patients.
However, sensitive and reliable analysis of
P. aeruginosa
remains a huge challenge. In this method, target recognition assists
the formation of a self-primer and initiates single-stranded chain
production. The produced single-stranded DNA chain is identified by
CRISPR-Cas12a, and consequently, the
trans
-cleavage
activity of the Cas12a enzyme is activated to parallelly digest Ag
+
aptamer sequences that are chelated with silver ions (Ag
+
). The released Ag
+
reacted with 3,3′,5,5′-tetramethylbenzidine
(TMB) for coloring. Compared with the traditional color developing
strategies, which mainly rely on the DNA hybridization, the color
developing strategy in this approach exhibits a higher efficiency
due to the robust
trans
-cleavage activity of the
Cas12a enzyme. Consequently, the method shows a low limit of detection
of a wide detection of 5 orders of magnitudes and a low limit of detection
of 21 cfu/mL, holding a promising prospect in early diagnosis of infections.
Herein, we develop a sensitive and reliable method for direct and
colorimetric detection of
P. aeruginosa
by integrating self-primer-assisted chain production and CRISPR-Cas12a-based
color reaction and believe that the established approach will facilitate
the development of bacteria-analyzing sensors.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.